Alligator Bioscience AB (ATORX)

Currency in SEK
0.0101
-0.0005(-4.72%)
Closed·
Earnings results expected today
Trading near 52-week Low
ATORX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.00960.0109
52 wk Range
0.00962.3765
Key Statistics
Prev. Close
0.0101
Open
0.0108
Day's Range
0.0096-0.0109
52 wk Range
0.0096-2.3765
Volume
124.64M
Average Volume (3m)
20.38M
1-Year Change
-99.2887%
Book Value / Share
0.0053
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ATORX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Alligator Bioscience AB News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Alligator Bioscience AB Earnings Call Summary for Q3/2026

  • Alligator Bioscience pivots to royalty model, owns 35% of AbClon's HLX22 interest, yielding up to 1.75% effective royalty rate on net sales.
  • Company holds SEK 41M cash post-rights issue; targeting SEK 1M monthly operating costs by Q2 2027 amid workforce reduction and wind-down.
  • First royalty income not expected until 2030 or later; HLX22 phase III gastric cancer data anticipated second half 2027.
  • Current cash insufficient to reach royalty phase; company dependent on warrant exercises in Jan 2027 and Jan 2028 for additional funding.
  • Shares down 1.85% to $0.0106, near 52-week low; market cap just $0.67M reflects weak financial health score of 1.11 and high financing risk.
Last Updated: 22-10-2026, 06:10 pm
Read Full Transcript

Earnings

Latest Release
26-08-2026
EPS / Forecast
-0.06 / --
Revenue / Forecast
288K / --
EPS Revisions
Last 90 days

ATORX Income Statement

Compare ATORX to Peers and Sector

Metrics to compare
ATORX
Peers
Sector
Relationship
P/E Ratio
−0.1x−2.7x−0.3x
PEG Ratio
0.00−0.050.00
Price/Book
2.0x4.0x2.6x
Price / LTM Sales
9.8x11.6x2.9x
Upside (Analyst Target)
-502.3%64.3%
Fair Value Upside
Unlock58.5%9.2%Unlock

Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Belgium. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 3 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage for the treatment of solid metastatic tumors. It also offers ALG.APV-527, a bispecific antibody that targets the 4-1BB and 5T4 molecules, which is in phase 2 clinical trial for the treatment of solid metastatic tumors; and ATOR-1017, a monoclonal antibody that stimulates the 4-1BB receptor on T cells and NK cells in the tumor, which is in phase 1 for the treatment of solid metastatic cancers; and HLX22, an antibody that treats metastatic, gastric, and breast cancers, which is in phase 3 clinical trial. In addition, the company develops products using its technology platforms, including ALLIGATOR-GOLD, a proprietary human antibody library; ALLIGATOR-FAB, which is built on multiple scaffolds with optimal drug development properties to further increase the structural diversity of generated antibodies; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. Further, it has collaboration and out-licensing agreements with Aptevo Therapeutics, Inc.; Orion Corporation.; BioArctic AB; Henlius Biotech, Inc.; and Abclon Inc. The company was incorporated in 2000 and is headquartered in Lund, Sweden.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
262.06M41.72%2.83M
Other Institutional Investors
40.83M6.50%440.95K
Public Companies & Retail Investors
325.22M51.78%3.51M
Total
628.11M100.00%6.78M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Alfred Berg Kapitalforvaltning AB41.72%26,20,55,7222,830
Nowo Global Fund41.72%26,20,55,7222,830

FAQ

What Is the Alligator Bioscience (ATORX) Share Price Today?

The Alligator Bioscience share price today is 0.0101.

What is the current Alligator Bioscience (ATORX) share price and day range?

As of 23-10-2026, the Alligator Bioscience share price is 0.0101, with a previous close of 0.0101. The share price has ranged from 0.0096 to 0.0109 today, while the 52-week range spans from 0.0096 to 2.3765.

What Is the Alligator Bioscience Market Cap?

As of today, Alligator Bioscience market cap is 6.6600M.

What Is the Alligator Bioscience (ATORX) Share Price Target?

The average 12-month share price target for Alligator Bioscience is 0.0560, with a high estimate of 0.056 and a low estimate of 0.056. 0 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +454.46% Upside potential.

What Is Alligator Bioscience's Earnings Per Share (TTM)?

The Alligator Bioscience EPS (TTM) is -0.24.

When Is the Next Alligator Bioscience Earnings Date?

Alligator Bioscience will release its next earnings report on 23-10-2026.

From a Technical Analysis Perspective, Is ATORX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

What Stock Exchange Does Alligator Bioscience Trade On?

Alligator Bioscience is listed and trades on the Stockholm Stock Exchange.

What Is the Stock Symbol for Alligator Bioscience?

The stock symbol for Alligator Bioscience is "ATORX."

How Many Times Has Alligator Bioscience Stock Split?

Alligator Bioscience has split 2 times.

How Many Employees Does Alligator Bioscience Have?

Alligator Bioscience has 11 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.